Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 12, 2024 13:30 ET | Source: Mangoceuticals, Inc.

MangoRx Appoints Dr. Douglas Christianson, N.D. as Director of the Medical Research and Product Innovation Department

DALLAS, TEXAS, July 12, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health...
July 11, 2024 08:15 ET | Source: Mangoceuticals, Inc.

MangoRx Announces Strategic Partnership for Expansion into Asia Pacific and Key Emerging Markets

DALLAS, TEXAS, July 11, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling a variety of men’s health...
June 06, 2024 08:30 ET | Source: Mangoceuticals, Inc.

MangoRx Receives Notice of Acceptance for Patent Application in Australia for Respiratory Illness and Preventive Care Technology

Dallas, Texas, June 06, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health...
June 04, 2024 16:00 ET | Source: Mangoceuticals, Inc.

MangoRx Receives Patent Notice of Allowance in Japan for Revolutionary Preventive Care Technology Acquired from Intramont Technologies

Dallas, Texas, June 04, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health...
June 04, 2024 08:00 ET | Source: Mangoceuticals, Inc.

MangoRx to Introduce “MOJO” Pharmaceutical Compounded Formula Featuring Enclomiphene Citrate and Pregnenolone for Treatment of Low Testosterone and Male Hormone Imbalances

MOJO to be offered as an Oral Dissolvable Tablet (ODT) marketed to younger male demographic as an alternative to PRIME Testosterone Replacement Therapy (TRT) Dallas, Texas, June 04, 2024 (GLOBE...
May 28, 2024 08:30 ET | Source: Mangoceuticals, Inc.

Mangoceuticals, Inc. Announces Completion of First Batch of Mango ED Products for Marketing and Distribution in Mexico and Latin American Markets

Dallas, Texas, May 28, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health...
May 23, 2024 08:30 ET | Source: Mangoceuticals, Inc.

MangoRx Engages Renown International Digital and Performance Marketing Company Crakmedia to Champion its Digital Marketing Efforts

Dallas, TX, May 23, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and...
May 21, 2024 08:30 ET | Source: Mangoceuticals, Inc.

MangoRx to Introduce Oral Semaglutide and Tirzepatide in Response to Increasing Patient Demand for GLP-1 Medications

Formulations to be marketed as “Slim” and “Trim” as an Oral Dissolvable Tablet (ODT) Dallas, TX, May 21, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”),...
May 16, 2024 16:40 ET | Source: Mangoceuticals, Inc.

MangoRx Reports Revenue Growth of 108% in Q1 2024 Fueled by Amplified Customer Acquisition and Early Market Penetration

Dallas, Texas, May 16, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health...
May 02, 2024 08:00 ET | Source: Mangoceuticals, Inc.

Mangoceuticals Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement and Conditional Approval of Compliance with Nasdaq’s Minimum Stockholders’ Equity Requirement

Dallas, Texas, May 02, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right